1267684-96-7

Upstream product

• 85963-90-2 methyl 2-(4-bromobenzoyl)-3-oxo-butanoate 
• 1228689-61-9 methyl 5-(4-bromophenyl)-3-methylisoxazole-4-carboxylate 
• 1280205-98-2 (5-(4-bromophenyl)-3-methylisoxazole-4-yl)methanol 
• 91182-60-4 5-(4-bromophenyl)-3-methylisoxazole-4-carboxylic acid 

Downstream Products

• 1280733-16-5 (3-benzyl-phenyl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol 
• 1280733-24-5 (5-benzyl-pyridin-3-yl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol 
• 1280732-85-5 (S)-1-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-1-ol 
• 1280732-59-3 1-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-yn-1-ol 
• 1280732-93-5 [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-[1-(3-trifluoromethyl-benzyl)-1H-[1,2,3]triazol-4-yl]-methanol 
• 1284212-22-1 N-[1-(4'-{4-[(5-Benzyl-[1,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarbonyl]-methanesulfonamide 
• 1280732-75-3 (S)-(5-benzyl[1,3,4]oxadiazol-2-yl)-[5-(4-bromophenyl)-3-methylisoxazol-4-yl]methanol 
• 1280732-72-0 (R)-(5-benzyl[1,3,4]oxadiazol-2-yl)-[5-(4-bromophenyl)-3-methylisoxazol-4-yl]methanol 
• 1280732-84-4 (S)-(1-benzyl[1,2,3]triazol-4-yl)-[5-(4-bromophenyl)-3-methylisoxazol-4-yl]methanol 
• 1280207-34-2 1-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-2,2-difluoro-but-3-en-1-ol 
• 1280206-11-2 5-(4-bromo-phenyl)-3-methyl-4-(4-phenyl-but-1-enyl)-isoxazole 
• 1280206-70-3 1-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-but-3-en-1-ol 
• 1280206-77-0 1-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-1-one 
• 1280206-71-4 (E)-1-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-but-3-en-1-ol 

Relevant academic research and scientific papers

Amide Bond Formation via the Rearrangement of Nitrile Imines Derived from N-2-Nitrophenyl Hydrazonyl Bromides

We report how the rearrangement of highly reactive nitrile imines derived from N-2-nitrophenyl hydrazonyl bromides can be harnessed for the facile construction of amide bonds. This amidation reaction was found to be widely applicable to the synthesis of primary, secondary, and tertiary amides and was used as the key step in the synthesis of the lipid-lowering agent bezafibrate. The orthogonality and functional group tolerance of this approach was exemplified by the N-acylation of unprotected amino acids.

POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Compounds as Lysophosphatidic Acid Receptor Antagonists

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in com